Beside further improvements concerning the identification of adequate tumor antigens, linker optimization as well as the discovery and validation of novel highly potent drugs, the site-specific conjugation of the payload to the antibody plays a crucial part in the design of next-generation ADCs.
In this regard, we developed TrypCo® technology, a versatile enzyme-based conjugation platform enabling efficient N- or C-terminal modification of basically any protein with a virtually unlimited variety of artificial functionalities like fluorescent probes, toxins or polymers. TrypCo® features a fast and efficient one-step labeling procedure under mild reaction conditions without the need of co-factors or special agents.
▶ Homogeneous product
▶ Efficient N- and C-terminal modification
▶ Short TrypTag recognition sequence (4 AA)
▶ Full control of conjugation sites and ratios
▶ Standardized labeling within minutes
▶ Simple synthesis of linker
▶ Full activity in biological buffers
▶ High flexibility towards linker and functionalities
▶ No co-factors or special agents necessary
▶ Straightforward upscaling
The TrypCo® technology features a high flexibility towards site of conjugation and the generated drug-to-antibody ratio (DAR). By combining the N- and C-terminal modification we are able to synthesize a comprehensive range of ADC’s with a defined DAR of 2, 4, 6 or 8. Additionally we engineered a set of different TrypCoZymes with orthogonal recognition sequences to enable the attachment of distinct payloads within one antibody to benefit from synergistic effects.
BIO International Convention 2019
3rd June 2019 - 6th June 2019
15th Annual PEGS Boston
8th April 2019 - 12th April 2019
Winner of the Poster competition in Session B (Poster B27).
9th World ADC Europe Summit 2019
4th March 2019 – 6th March 2019
World ADC London is Europe’s leading antibody-drug conjugate conference. Across three days, this comprehensive three streamed programme will cover every element of ADCs from discovery and development to manufacturing and clinical use. Attend World ADC London to validate novel ADC targets, improve understanding of mechanisms driving toxicity in clinical development and robustly scale up process development to support commercialisation.
BTI GmbH will be presenting its novel TrypCo® technology at the event.
We offer the talk, which Marcus Böhme gave during the 9th World ADC Europe 2019, as a download
Dr. Thomas Richter, Managing Director/CEO
Thomas joined BTI as Managing Director in January 2014 shortly after its foundation. He implemented BTI’s translation approach from academic research to industrial use by establishing first collaboration projects. Thomas is a biochemist and economist by profession and looked back on a successful investment banking carrier of more than 10 years before he switched to the pharmaceutical industry sector. Since then he held several Senior Management and Sales position and was more than 3 years responsible for an US-based CDMO as Managing Director.
René Wartner, Andreas Simon and Marcus Böhme (from left to right) are the scientific team behind the TrypCo® technology. They all graduated in Biochemistry/Biotechnology at the Martin-Luther-University Halle-Wittenberg and possess several years of experience in the field of directed evolution, enzyme engineering and bioconjugates. When starting the TrypCo®-related cooperative project in 2015 they joined BTI as they were involved in the development of these enzymes from the early stage beginning.
The team is scientifically advised by Prof. Frank Bordusa (Head of Naturstoffbiochemie at the Martin-Luther-University Halle-Wittenberg) being an expert in peptide chemistry and applied biocatalysis. His work and advice lays the foundation for developing the TrypCoZymes making him a valuable and indispensable academic partner.